Brincidofovir for polyomavirus-associated nephropathy after allogeneic hematopoietic stem cell transplantation

Am J Kidney Dis. 2015 May;65(5):780-4. doi: 10.1053/j.ajkd.2014.11.020. Epub 2015 Jan 17.

Abstract

Polyomavirus-associated nephropathy (PVAN) is common in patients who have undergone kidney transplantation and has been reported in hematopoietic stem cell (HSC) transplant recipients. Aside from reduction of immunosuppression, few therapeutic options exist for treatment of PVAN. We report a case of PVAN in a severely immunocompromised allogeneic HSC transplant recipient that was treated with brincidofovir without reduction of immunosuppression. We review our institutional experience of PVAN in HSC transplantation and discuss the potential use of brincidofovir for treatment.

Keywords: BK viremia; BK virus; Polyomavirus-associated nephropathy (PVAN); brincidofovir; hematopoietic stem cell (HSC) transplantation; kidney failure.

Publication types

  • Case Reports

MeSH terms

  • BK Virus*
  • Cytomegalovirus Infections / drug therapy*
  • Cytosine / analogs & derivatives*
  • Cytosine / therapeutic use
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunocompromised Host
  • Kidney Diseases / drug therapy*
  • Kidney Diseases / virology*
  • Male
  • Middle Aged
  • Organophosphonates / therapeutic use*
  • Polyomavirus
  • Polyomavirus Infections / drug therapy*
  • Tumor Virus Infections / drug therapy*
  • Viremia / drug therapy

Substances

  • Organophosphonates
  • brincidofovir
  • Cytosine